https://canada.googleblog.com/
Morgan Stanley Maintains Underweight on Veracyte, Lowers Price Target to $42
Morgan Stanley maintains Veracyte (NASDAQ:VCYT) with a Underweight and lowers the price target from $45 to $42.
Related Posts
Keybanc Maintains Overweight on ICU Medical, Lowers Price Target to $225
Keybanc analyst Matthew Mishan maintains ICU Medical (NASDAQ:ICUI) with a Overweight and lowers the price target from $230 to $225.
Nasdaq Has Approved Bitcoin Miners ETF By Valkyrie
https://twitter.com/BreakingCrypto5/status/1490710989523890179
Helius Medical’s Neuromodulation Stimulator Nabs FDA Breakthrough Tag
The FDA has granted Breakthrough Device Designation to Helius Medical Technologies Inc’s (NASDAQ:HSDT) PoNS device. Related content: Benzinga’s Full FDA Calendar. The designation…